Solid Biosciences Inc. is a Strong Buy driven by positive FDA alignment on phase 3 IMPACT DUCHENNE trial for SGT-003. Read more on SLDB stock here.
Origami is collaborating with Ipsen to develop molecules designed to remove or correct abnormal proteins in neurodegenerative diseases.
The study uncovers obesity's genetic links to chronic diseases, offering insights into multimorbidity and the potential for ...
Among them was David Liu, a biochemist at the Broad Institute and Harvard University in Cambridge, Massachusetts. Liu isn’t a ...
A clinical trial led by Kirby Institute at UNSW Sydney has found that point-of-care testing for hepatitis B DNA is as ...
A University of Houston psychology professor is challenging the notion that dyslexia, or specific reading disorder, stems ...
With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...
Despite its strong influence, APOE is not the sole cause of Alzheimer’s or other dementias. Even among people with the highest genetic risk, those who carry two ε4 variants, lifetime risk of Alzheimer ...
As Chris Hemsworth lets fans into his family's struggle with Alzheimer's, he's curious how the mental health revelation will impact his career.
Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after injury. For some, however, muscle development goes awry, leading to weakness, ...
Researchers reprogrammed bacterial bridge recombinases to edit large genomic regions in mammalian cells, revealing a ...
Neurodegenerative diseases (NDs) are among the most urgent global health challenges, affecting millions worldwide and placing a growing burden on healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results